In human cholangiocarcinoma, activated YAP is associated with poor prognosis, chemoresistance, angiogenesis, and chromosomal instability (Marti et al., 2015; Wu et al., 2016; Rizvi et al., 2018), and high TAZ expression correlates with a decreased survival after tumor resection (Xiao et al., 2016). The gene discussed is YAP1; the disease is cholangiocarcinoma.